Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 3Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 1Multiple Myeloma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 391Carboplatin 345pembrolizumab 332Gemcitabine 332Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 288Bevacizumab 254Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 191fludarabine 178Oxaliplatin 178Pemetrexed 154Doxorubicin 153Irinotecan 149Leucovorin 145Etoposide 144Cytarabine 134Cetuximab 131fludarabine phosphate 129Bortezomib 129Lenalidomide 126Erlotinib Hydrochloride 121Filgrastim 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × crenigacestat × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT03502577 2024-01-08

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡